These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1427452)

  • 21. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine.
    De Sanctis V; Pinamonti A; Di Palma A; Sprocati M; Atti G; Gamberini MR; Vullo C
    Eur J Pediatr; 1996 May; 155(5):368-72. PubMed ID: 8741032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy for beta-thalassemia--a paradigm for the treatment of genetic disorders.
    Dover GJ; Valle D
    N Engl J Med; 1994 Sep; 331(9):609-10. PubMed ID: 8047089
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
    De Sanctis V; Roos M; Gasser T; Fortini M; Raiola G; Galati MC;
    J Pediatr Endocrinol Metab; 2006 Apr; 19(4):471-80. PubMed ID: 16759032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of haemochromatotic cardiomyopathy in beta thalassaemia by chelation therapy.
    Politi A; Sticca M; Galli M
    Br Heart J; 1995 May; 73(5):486-7. PubMed ID: 7786668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Desensitization treatment for anaphylactoid reactions to desferrioxamine in a pediatric patient with thalassemia.
    La Rosa M; Romeo MA; Di Gregorio F; Russo G
    J Allergy Clin Immunol; 1996 Jan; 97(1 Pt 1):127-8. PubMed ID: 8568125
    [No Abstract]   [Full Text] [Related]  

  • 26. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use.
    Ward A; Caro JJ; Green TC; Huybrechts K; Arana A; Wait S; Eleftheriou A
    BMC Clin Pharmacol; 2002 Apr; 2():3. PubMed ID: 12015817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment.
    Ambrosetti U; Dondè E; Piatti G; Cappellini MD
    Pharmacol Res; 2000 Nov; 42(5):485-7. PubMed ID: 11023713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth plate injury of the long bones in treated beta-thalassemia.
    Orzincolo C; Scutellari PN; Castaldi G
    Skeletal Radiol; 1992; 21(1):39-44. PubMed ID: 1546335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ocular involvement correlated with age in patients affected by major and intermedia beta-thalassemia treated or not with desferrioxamine.
    Rinaldi M; Della Corte M; Ruocco V; D'Onofrio C; Zanotta G; Romano A
    Metab Pediatr Syst Ophthalmol (1985); 1993; 16(1-2):23-5. PubMed ID: 8259071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allergy to desferrioxamine.
    Romeo MA; Di Gregorio F; Schiliro G
    J Inherit Metab Dis; 1984; 7(3):121. PubMed ID: 6438394
    [No Abstract]   [Full Text] [Related]  

  • 31. MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major.
    Miller TT; Caldwell G; Kaye JJ; Arkin S; Burke S; Brill PW
    Pediatr Radiol; 1993; 23(7):523-4. PubMed ID: 8309753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute renal failure following deferoxamine overdose.
    Li Volti S; Maccarone C; Li Volti G; Romeo MA
    Pediatr Nephrol; 2003 Oct; 18(10):1078-9. PubMed ID: 12920634
    [No Abstract]   [Full Text] [Related]  

  • 33. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions.
    Freedman MH; Grisaru D; Olivieri N; MacLusky I; Thorner PS
    Am J Dis Child; 1990 May; 144(5):565-9. PubMed ID: 2330923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac determinants of survival in beta-thalassemia.
    Efthimiadis GK; Hassapopoulou HP; Tsikaderis DD; Karvounis HI; Giannakoulas G; Parharidis GE
    Haematologica; 2006 Dec; 91(12 Suppl):ELT11. PubMed ID: 17194671
    [No Abstract]   [Full Text] [Related]  

  • 35. Desferrioxamine in acute iron poisoning.
    Chan KW; Bond M; Fernandez W
    Lancet; 1992 Jun; 339(8809):1601-2. PubMed ID: 1351566
    [No Abstract]   [Full Text] [Related]  

  • 36. Reappraisal of high-dose desferrioxamine therapy.
    Schilirò G; Russo A
    Acta Haematol; 1986; 76(1):63-4. PubMed ID: 3098031
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of desferoxamine on retinal and visual function.
    Lu M; Hansen RM; Cunningham MJ; Eklund SE; Fulton AB
    Arch Ophthalmol; 2007 Nov; 125(11):1581-2. PubMed ID: 17998528
    [No Abstract]   [Full Text] [Related]  

  • 38. Case report 744. Deferoxamine-induced skeletal dysplasia.
    Borenstein ZC; Hyman CB; Rimoin DL; Chapman CL; Lachman R
    Skeletal Radiol; 1992; 21(8):534-7. PubMed ID: 1465648
    [No Abstract]   [Full Text] [Related]  

  • 39. Aluminum toxicity due to intravenous injection of boiled methadone.
    Yong RL; Holmes DT; Sreenivasan GM
    N Engl J Med; 2006 Mar; 354(11):1210-1. PubMed ID: 16540630
    [No Abstract]   [Full Text] [Related]  

  • 40. Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients.
    Costagliola DG; de Montalembert M; Lefrère JJ; Briand C; Rebulla P; Baruchel S; Dessi C; Fondu P; Karagiorga M; Perrimond H
    Br J Haematol; 1994 Aug; 87(4):849-52. PubMed ID: 7986727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.